Search Results - "BONIFATI, D. M"

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy by PEGORARO, E, HOFFMAN, E. P, LANFRANCHI, G, ANGELINI, C, KESARI, A, LEE, I, GORDISH-DRESSMAN, H, DEVANEY, J. M, MCDONALD, C. M, PIVA, L, GAVASSINI, B. F, CAGNIN, S, ERMANI, M, BELLO, L, SORARU, G, PACCHIONI, B, BONIFATI, M. D

“…Duchenne muscular dystrophy (DMD) is the most common single-gene lethal disorder. Substantial patient-patient variability in disease onset and progression and…”
Get full text

Development and validation of the Myasthenia Gravis TeleScore (MGTS) by Pasqualin, F., Guidoni, S. V., Albertini, E., Ermani, M., Frangiamore, R., Vanoli, F., Antozzi, C., Mantegazza, R., Bonifati, D. M.

“…Objective The aim of our study was to validate the Myasthenia Gravis TeleScore (MGTS), a scale for the evaluation of MG patients in telemedicine. Introduction…”
Get full text

The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy by Bonifati, D M, Witchel, S F, Ermani, M, Hoffman, E P, Angelini, C, Pegoraro, E

“…Background: Steroid administration is beneficial in Duchenne muscular dystrophy (DMD), but the response, incidence, and the severity of side effects are…”
Get full text

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy by Bonifati, Marco Domenico, Ruzza, Giampietro, Bonometto, Piero, Berardinelli, Angela, Gorni, Kseniya, Orcesi, Simona, Lanzi, Giovanni, Angelini, Corrado

“…We randomized 18 Duchenne muscular dystrophy (DMD) boys whose age ranged from 5.2 to 14.6 years (mean, 7.3 years) for treatment with either deflazacort (0.9…”
Get full text

The quality of neurology residency programmes in Italy by Capobianco, M, Mancuso, M, Triggiani, L, Scaravilli, T, Bonifati, D M

Get more information

Long-term cyclosporine treatment in a group of severe myasthenia gravis patients by BONIFATI, D. M, ANGELINI, C

“…We evaluated cyclosporine A (CsA) treatment in 9 patients (6 female and 3 male), 16-63 years old, with severe myasthenia gravis (MG) for a mean period of 2…”
Get full text

Quality of neurology residency programmes: an Italian survey by Bonifati, D. M., Scaravilli, T., Leone, M., De Biasia, F., Naccarato, M., Ottina, M., Triggiani, L., Mancuso, M.

“…In recent years there has been a growing interest in medical and particularly neurological education and how this should be related to the needs for patient…”
Get full text

Structural and functional anatomy of the globular domain of complement protein C1q by Kishore, Uday, Ghai, Rohit, Greenhough, Trevor J., Shrive, Annette K., Bonifati, Domenico M., Gadjeva, Mihaela G., Waters, Patrick, Kojouharova, Mihaela S., Chakraborty, Trinad, Agrawal, Alok

“…C1q is the first subcomponent of the classical pathway of the complement system and a major connecting link between innate and acquired immunity. As a…”
Get full text

New therapies in muscular dystrophies by Angelini, C, Bonifati, D M

“…Muscular dystrophies are a group of hereditary muscle disorders that often result in severe disability. Curative therapy is not yet available for muscular…”
Get full text

Steroids in muscular dystrophy: where do we stand? by Dubrovsky, Alberto L, Angelini, Corrado, Bonifati, Domenico M, Elena Pegoraro, Mesa, Lilia

Get full text

Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents by BONIFATI, Domenico Marco, ORI, Carlo, ROSSI, Carlo Riccardo, CAIRA, Stefania, FANIN, Marina, ANGELINI, Corrado

“…To evaluate the incidence and entity of muscle damage after hyperthermic limb perfusion (HLP) with doxorubicin or melphalan, two widely used chemotherapeutic…”
Get full text

Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures by Farrugia, Maria Elena, Bonifati, Domenico Marco, Clover, Linda, Cossins, Judy, Beeson, David, Vincent, Angela

“…Abstract A proportion of patients with myasthenia gravis (MG) do not have antibodies to the acetylcholine receptor (AChR). Some of these patients have…”
Get full text

Desmopressin Acetate in Percutaneous Ultrasound-Guided Kidney Biopsy: A Randomized Controlled Trial by Manno, Carlo, MD, Bonifati, Carmen, MD, Torres, Diletta Domenica, MD, Campobasso, Nicla, MD, Schena, Francesco Paolo, MD

“…Background Bleeding complications occur in one-third of percutaneous kidney biopsies and increase costs of the hospital stay. The aim of the study was to…”
Get full text

Phenotype, genotype, and worldwide genetic penetrance of LRRK2 -associated Parkinson's disease: a case-control study by Healy, Daniel G, MD, Falchi, Mario, PhD, O'Sullivan, Sean S, MD, Bonifati, Vincenzo, MD, Durr, Alexandra, MD, Bressman, Susan, MD, Brice, Alexis, MD, Aasly, Jan, MD, Zabetian, Cyrus P, MD, Goldwurm, Stefano, PhD, Ferreira, Joaquim J, MD, Tolosa, Eduardo, MD, Kay, Denise M, PhD, Klein, Christine, MD, Williams, David R, MD, Marras, Connie, MD, Lang, Anthony E, MD, Wszolek, Zbigniew K, MD, Berciano, Jose, MD, Schapira, Anthony HV, MD, Lynch, Timothy, MD, Bhatia, Kailash P, MD, Gasser, Thomas, MD, Lees, Andrew J, MD, Wood, Nicholas W, MD

“…Summary Background Mutations in LRRK2 , the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2…”
Get full text

Neurology residency training in Europe: an Italian perspective by Facheris, Maurizio, Mancuso, Michelangelo, Scaravilli, Tomaso, Bonifati, Domenico Marco

“…Education is the most important part of medical-science training. Assessment of training programmes and examination of trainees' skills are necessary to…”
Get more information

Lack of association between acetylcholine receptor ϵ polymorphisms and early-onset myasthenia gravis by Bonifati, Domenico Marco, Willcox, Nick, Vincent, Angela, Beeson, David

“…A patient with mutations in the acetylcholine receptor (AChR) ϵ subunit, who subsequently developed autoimmune myasthenia gravis (MG), led us to search for ϵ…”
Get full text